While the US biotech sector has boomed during the pandemic, with dozens of start-ups going public via mergers with special purpose acquisition corporations (SPACs), European companies have so far largely missed out.
That is about to change, with UK-based 4D Pharma, plc due to complete a NASDAQ listing this month, by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?